ArticleNature communications2017
Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Bone-on-a-Chip Systems for Hematological Cancers.Biosensors · 2025Review
- Article
- A New Microfluidic Device to Facilitate Functional Precision Medicine Assays.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.JCO precision oncology · 2024Article
- Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements.Communications biology · 2022Article
- Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction.Translational oncology · 2022Article
- Combining denoising of RNA-seq data and flux balance analysis for cluster analysis of single cells.BMC bioinformatics · 2022Article
- Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets.Nature communications · 2022Article
- A transcriptional biosensor to monitor single cancer cell therapeutic responses by bioluminescence microscopy.Theranostics · 2022Article
- Fabricating Silicon Resonators for Analysing Biological Samples.Micromachines · 2021Review
- Review
- Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.Theranostics · 2021Review
- Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma.Cancers · 2020Review
- COVID-19 and myeloma: what are the implications for now and in the future?British journal of haematology · 2020Article
- Identifying fates of cancer cells exposed to mitotic inhibitors by quantitative phase imaging.The Analyst · 2019Article
- Constitutive expression of a fluorescent protein reports the size of live human cells.Molecular biology of the cell · 2019Article
- Noninvasive monitoring of single-cell mechanics by acoustic scattering.Nature methods · 2019Article
- Alveolar proteins stabilize cortical microtubules in Toxoplasma gondii.Nature communications · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Multiple myeloma (MM) has benefited from significant advancements in treatment that have improved outcomes and reduced morbidity. However, the disease remains incurable and is characterized by high rates of drug resistance and relapse. Consequently, methods to select the most efficacious therapy are of great interest. Here we utilize a functional assay to assess the ex vivo drug sensitivity of single multiple myeloma cells based on measuring their mass accumulation rate (MAR). We show that MAR accurately and rapidly defines therapeutic susceptibility across human multiple myeloma cell lines to a gamut of standard-of-care therapies. Finally, we demonstrate that our MAR assay, without the need for extended culture ex vivo, correctly defines the response of nine patients to standard-of-care drugs according to their clinical diagnoses. This data highlights the MAR assay in both research and clinical applications as a promising tool for predicting therapeutic response using clinical samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.